Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Shuffle: Simmons Out, Brandicourt In At Emerging Markets And Established Products Unit

This article was originally published in The Pink Sheet Daily

Executive Summary

David Simmons, head of established products and emerging markets at Pfizer, has jumped ship to lead global CRO PPD Inc. Olivier Brandicourt, currently head of primary care at the big pharma, will take Simmons’ place.

You may also be interested in...



Bayer Names Pfizer’s Brandicourt Healthcare Division CEO

The broadly experienced pharmaceutical executive – who has specialized particularly in emerging markets and infectious diseases – inherits a healthcare division that is in the midst of several product launches and has few near-term patent expirees.

People In The News: Tracking The Latest Industry Personnel Moves

New top leadership at PPD and Promedior; Pfizer names new presidents at two business units; Former FDA Commissioner von Eschenbach and former HHS Secretary Thompson take on board of director roles. More personnel announcements in this month’s column.

Post Biocon, Pfizer Pushes Forward On Biosimilar MABs

Biosimilars pioneers face a steep learning curve and multiple surprises, as shown by Pfizer’s recent and expensive backtrack on its deal with India’s Biocon. But Pfizer says the setback has reaffirmed its strategy as it pushes ahead on its own with a monoclonal antibody program, led by a biosimilar rituximab.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS074161

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel